In September 2017, Evotec and Exscientia Ltd ("Exscientia") announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia. Through this investment, Evotec became the first strategic shareholder in the UK-based company. Exscientia is focused on Artificial Intelligence ("AI")-driven drug discovery and design.
Exscientia and Evotec have cooperated since early 2016 to advance small molecules and bispecific small molecules in immuno-oncology. The ongoing success of this partnership was the basis for an expanded and deepened corporate relationship. Exscientia is the world leader in developing and applying AI approaches specifically to design new and better therapeutic molecules in a faster and more cost-effective manner. Exscientia's approach fuses the power of AI with the discovery experience of seasoned drug hunters and chemistry experts. Exscientia uses its funds to drive higher value partner programmes and expand discovery on its automated design platform.
In January 2019, Evotec announced an additional investment of approximately $ 6 m towards Exscientia’s Series B funding round (Series B), in which Exscientia raised a total of $ 26 m. Bristol Myers Squibb (formerly Celgene Corporation) and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round.
In May 2020, Evotec announced that the Company had participated in Exscientia's latest funding round (Series C) which raised a total of $ 60 m from the existing investors' consortium and new investor Novo Holdings AS.
In March 2021, Exscientia announced that funds managed by BlackRock joined the Company’s Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $ 100 m in funding.
In April 2021, Evotec and Exscientia announced that the most advanced asset arising from their joint venture with has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec.
Exscientia will lead further clinical development of the molecule and Evotec will retain co-ownership rights throughout clinical development.
Exscientia has active collaborations with, amongst others, Bayer, Bristol Myers Squibb, GSK, Roche, Sanofi and Sumitomo Dainippon.
Here you can find more information about Exscientia.